Venetoclax shows strongest differential ex vivo response in T-PLL samples and is correlated with BCL-2 expression. (A) Lymph node and liquid biopsies were taken from consenting patients and used for expression profiling via TMAs and ex vivo drug-response profiling (n = 86). (B) Volcano blot, demonstrating mean differential AUCs (ΔAUCs) plotted for individual compounds comparing ex vivo effects in T-PLL vs non-T-PLL samples (n of compounds = 106). Blue circles indicate compounds hitting more specifically T-PLL than non-T-PLL samples (negative ΔAUCs). Gray circles indicate compounds hitting more specifically non-T-PLL than T-PLL samples (positive ΔAUCs). Venetoclax is highlighted in red as the most specific T-PLL compound identified in the drug screening. (C) AUCs of venetoclax in individual ex vivo samples stratified by indication (n = 86). (D) Comparison of AUCs of venetoclax and corresponding BCL-2 expression score by indication (n = 37). (E) Correlation of MCL-1 and BCL-XL expression scores of individual samples (n = 34). B-ALL, B-cell acute lymphoblastic leukemia; T-LBL, T-cell lymphoblastic lymphoma; T-NHL, T-cell non-Hodgkin lymphoma.